ProShares Ultra NASDAQ Biotechnology
31 hedge funds and large institutions have $19.8M invested in ProShares Ultra NASDAQ Biotechnology in 2016 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 4 increasing their positions, 9 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
more ownership
Funds ownership: →
more funds holding in top 10
Funds holding in top 10: →
less funds holding
Funds holding: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
31% less capital invested
Capital invested by funds: $28.7M → $19.8M (-$8.93M)
32% less call options, than puts
Call options by funds: $6.49M | Put options by funds: $9.59M
56% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 9
Holders
31
Holding in Top 10
1
Calls
$6.49M
Puts
$9.59M
Top Buyers
| 1 | +$466K | |
| 2 | +$441K | |
| 3 | +$413K | |
| 4 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$389K |
| 5 |
Wolverine Trading
Chicago,
Illinois
|
+$274K |
Top Sellers
| 1 | -$2.23M | |
| 2 | -$1.14M | |
| 3 | -$998K | |
| 4 |
PCA
Private Capital Advisors
Darien,
Connecticut
|
-$831K |
| 5 |
TFA
Toth Financial Advisory
Leesburg,
Virginia
|
-$790K |